Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9390
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Garay-Aramburu, G. | - |
dc.contributor.author | Hunt, Adrian | - |
dc.contributor.author | Arruabarrena, C. | - |
dc.contributor.author | Mehta, H. | - |
dc.contributor.author | Invernizzi, A. | - |
dc.contributor.author | Gabrielle, P. H. | - |
dc.contributor.author | Guillaumie, T. | - |
dc.contributor.author | Wolff, B. | - |
dc.contributor.author | Gillies, M. C. | - |
dc.contributor.author | Zarranz-Ventura, J. | - |
dc.date.accessioned | 2024-03-19T04:48:35Z | - |
dc.date.available | 2024-03-19T04:48:35Z | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | Scientific Reports 14(1):6122, 2024 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9390 | - |
dc.description.abstract | To compare baseline characteristics, initial response and 12-month efficacy and safety outcomes in eyes with branch and central retinal vein occlusion (BRVO and CRVO) treated with dexamethasone implants (DEX) or anti-vascular endothelial growth factor (anti-VEGF) we performed a multi-centre, retrospective and observational study using Fight Retinal Blindness! Registry. Of 725 eligible eyes, 10% received DEX initially with very frequent adjunctive anti-VEGF (BRVO-DEX 49%, CRVO-DEX 60%). The primary outcome of mean adjusted change in VA at 12 months with DEX and anti-VEGF initiated groups were not statistically significantly different (BRVO: DEX + 6.7, anti-VEGF + 10.6 letters; CRVO: DEX + 2.8, anti-VEGF + 6.8 letters). DEX initiated eyes had fewer injections and visits than anti-VEGF initiated eyes. The BRVO-DEX eyes had greater initial mean changes in VA and central subfield thickness (CST) and achieved inactivity sooner than BRVO-anti-VEGF eyes. The mean CST after the first three months was above 350 mum in all but the BRVO-anti-VEGF group, suggesting undertreatment. In routine care DEX is uncommonly used when available as initial treatment of BRVO and CRVO requiring supplemental anti-VEGF within the first year. The 12-month outcomes were similar, but DEX initiated eyes had fewer injections and visits but more episodes of raised IOP Vs those starting anti-VEGF. | - |
dc.title | Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.1038/s41598-024-56581-6 | - |
dc.subject.keywords | Retinal Vein Occlusion | - |
dc.subject.keywords | Dexamethasone | - |
dc.subject.keywords | Glucocorticoids | - |
dc.subject.keywords | Vascular Endothelial Growth Factor A | - |
dc.subject.keywords | Macular Edema | - |
dc.subject.keywords | Intravitreal Injections | - |
dc.identifier.journaltitle | Scientific Reports | - |
dc.identifier.department | Ophthalmology | - |
dc.contributor.wslhd | Hunt, Adrian | - |
dc.type.studyortrial | Observational Study | - |
dc.identifier.pmid | 38480837 | - |
dc.identifier.facility | Westmead | - |
Appears in Collections: | Westmead Hospital 2019 - 2024 |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.